高糖对肾小管上皮细胞脂质代谢影响及罗格列酮的干预研究

目的探讨高糖环境中肾小管上皮细胞脂质代谢变化,以及罗格列酮对其干预作用。方法体外培养HKC细胞,随机分为正常糖组、高糖组、罗格列酮干预组,采用油红染色检测细胞内脂质,免疫细胞化学和WesternBlot检测固醇调节元件结合蛋白1(sterolregulatory element binding protein-1,SREBP-1)表达。结果与正常糖组比较,高糖培养的肾小管上皮细胞内出现明显脂滴;免疫细胞化学、WesternBlot检测发现固醇调节元件结合蛋白1表达于胞浆,12、24、48、72h固醇调节元件结合蛋白1前体和成熟体表达高糖组均高于正常对照组,差异有统计学意义,其中以48h表达量最大(前体2.334±0.045,成熟体1.082±0.040),罗格列酮组相对于高糖组,前体和成熟体表达均下降,脂滴形成有所减少。结论高糖可诱导肾小管上皮细胞固醇调节元件结合蛋白1前体和成熟体表达升高,进一步导致脂质合成增多;罗格列酮减少脂质合成可能是部分通过抑制固醇调节元件结合蛋白1表达而实现。     

Rosiglitazone protects human neuroblastoma SH-SY5Y cells against acetaldehyde-induced cytotoxicity

Acetaldehyde, an inhibitor of mitochondrial function, has been widely used as a neurotoxin because it elicits a severe Parkinson's disease-like syndrome with elevation of the intracellular reactive oxygen species level and apoptosis. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, has been known to show various non-hypoglycemic effects, including anti-inflammatory, anti-atherogenic, and anti-apoptotic. In this study, we investigated the protective effects of rosiglitazone on acetaldehyde-induced apoptosis in human neuroblastoma SH-SY5Y cells and attempted to examine its mechanism. Acetaldehyde-induced apoptosis was moderately reversed by rosiglitazone treatment. Our results suggest that the protective effects of rosiglitazone on acetaldehyde-induced apoptosis may be ascribed to ability to induce the expression of anti-oxidant enzymes and to regulate Bcl-2 and Bax expression. These data indicate that rosiglitazone may provide a useful therapeutic strategy for the prevention of progressive neurodegenerative disease such as Parkinson's disease.     

PPAR??激动剂罗格列酮对人乳腺癌细胞生长 抑制及诱导凋亡作用研究

目的:观察氧化酶体激活物增殖受体(PPARγ)激动剂罗格列酮(ROZ)在体外激活PPARγ后对MCF-7细胞的生长抑制及诱导凋亡作用。方法:MTT法检测ROZ对MCF-7细胞的生长抑制作用;集落形成实验观察ROZ对MCF-7细胞集落形成的影响;不同浓度ROZ作用72h,Hoechst33342染色观察MCF-7细胞的形态变化,流式细胞光度分析术(FCM)检测凋亡细胞百分率以及ROZ对细胞周期的影响;Western blot方法检测ROZ对MCF-7细胞Bcl-2、Caspase-3表达的影响。结果:ROZ可呈剂量依赖性抑制MCF-7细胞的生长及集落形成。ROZ浓度为6×10-5M和3×10-4M时则G1期细胞数明显增加,S期相应减少。Hoechst33342染色经ROZ处理的肿瘤细胞染色质呈颗粒状,且有凋亡小体出现。FCM检测结果显示,ROZ作用72h凋亡细胞数达22.05%。Western blot提示ROZ可抑制Bcl-2表达,促进Caspase3表达。结论:ROZ在体外可抑制MCF-7细胞的增殖并诱导其凋亡,这可能与其抑制Bcl-2表达、促进caspase3表达有关。提示ROZ有望成为乳腺癌治疗药或肿瘤治疗的辅助用药,PPARγ有潜力成为肿瘤治疗的新靶点。     

Rosiglitazone inhibits endothelial proliferation and angiogenesis

Rosiglitazone, an insulin sensitizer, is known to offer beneficial effects in retarding atherosclerotic vascular diseases. Since proliferation and angiogenesis are involved in initiation and plaque instability, two critical steps in the cardiovascular events, this study was designed to evaluate the mechanisms of rosiglitazone on endothelial proliferation and angiogenesis. Rosiglitazone-treated human umbilical vein endothelial cells were analyzed for growth rate by use of cell number counting, 3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide assay as well as 3H-thymidine incorporation. Cell cycle analysis was detected by flow cytometry and cell cycle-related proteins were measured by Western blot. Effects of rosiglitazone on angiogenesis were assessed by vascular endothelial growth factor (VEGF)-induced tube formation and wound-healing migration. Furthermore, effects of rosiglitazone on actin stress fiber were observed under confocal microscopy. Our data showed that rosiglitazone inhibits endothelial proliferation in a dose-dependent manner. Rosiglitazone caused endothelial arrest at G1 phase via affecting several cell cycle-related proteins that led to attenuate phosphorylation of retinoblastoma protein. Rosiglitazone markedly decreased VEGF-induced tube formation and endothelial cell migration, which might be explained by a disorganization of the actin cytoskeleton. Our data suggest that both anti-proliferative and anti-angiogenic activities in endothelial cells might account for the greater than expected beneficial effects of rosiglitazone for the treatment and prevention of atherosclerosis.     

Rosiglitazone transiently disturbs calcium homeostasis in monocytic cells

The PPARγ agonist Rosiglitazone exerts anti-hyperglycaemic effects by regulating the long-term expression of genes involved in metabolism, differentiation and inflammation. In the present study, Rosiglitazone treatment rapidly inhibited (5-30 min) the ER Ca²⁺ ATPase SERCA2b in monocytic cells (IC₅₀ = 1.88 μM; p < 0.05), thereby disrupting short-term Ca²⁺ homeostasis (resting [Ca²⁺]_cyto = 121.2 ± 2.9% basal within 1 h; p < 0.05). However, extended Rosiglitazone treatment (72 h) induced dose-dependent SERCA2b up-regulation, and restored calcium homeostasis, in monocytic cells (SERCA2b mRNA: 138.7 ± 5.7% basal (1 μM)/215.0 ± 30.9% basal (10 μM); resting [Ca²⁺]_cyto = 97.3 ± 8.3% basal (10 μM)). As unfavourable cardiovascular outcomes, possibly related to disrupted cellular Ca²⁺ homeostasis, have been linked to Rosiglitazone, this effect may be of clinical interest. In contrast, in PPRE-luciferase reporter-gene assays, Rosiglitazone induced non-dose-dependent PPARγ-dependent effects (1 μM: 152.5 ± 4.9% basal; 10 μM: 136.1 ± 5.1% basal (p < 0.05 for 1 μM vs. 10 μM)). Thus, we conclude that Rosiglitazone can exert PPARγ-independent non-genomic effects, such as the SERCA2b inhibition seen here, but that long-term Rosiglitazone treatment did not perturb resting [Ca]_cyto in this study.     

Rosiglitazone stimulates the release and synthesis of insulin by enhancing GLUT-2, glucokinase and BETA2/NeuroD expression

Peroxisome proliferator-activated receptor (PPAR)-γ is a member of the nuclear receptor superfamily, and its ligands, the thiazolidinediones, might directly stimulate insulin release and insulin synthesis in pancreatic β-cells. In the present study, we examined the effects of rosiglitazone (RGZ) on insulin release and synthesis in pancreatic β-cell (INS-1). Insulin release and synthesis were stimulated by treatment with RGZ for 24 h. RGZ upregulated the expressions of GLUT-2 and glucokinase (GCK). Moreover, it was found that RGZ increased the expression of BETA2/NeuroD gene which could regulate insulin gene expression. These results suggest that RGZ could stimulate the release and synthesis of insulin through the upregulation of GLUT-2, GCK, and BETA2/NeuroD gene expression.     

马来酸罗格列酮对人肺腺癌（A549）细胞中PGC-1α表达及增殖的影响

摘要：为探讨马来酸罗格列酮对肺腺癌（A549）细胞中PGC-1a表达和活性的影响,以及抑制细胞增殖的机制,我们首先构建了pGL3-PGC-1a promoter重组质粒,转染人肺腺癌A549细胞,用双荧光素酶报告基因系统检测马来酸罗格列酮对PGC-1a启动子转录活性的影响;实时定量PCR检测胞内PGC-1a mRNA的表达;用Mitotracker green染色, 流式细胞仪检测线粒体质量;细胞计数检测马来酸罗格列酮对A549细胞体外增殖的影响。结果显示,马来酸罗格列酮能够抑制pGL3-PGC-1apromoter重组质粒的转录活性,降低A549细胞PGC-1amRNA水平的表达及线粒体质量,具有明显的剂量依赖性（P<0.05）。其抑制PGC-1a表达和活性的IC50（约为80 umol/L）与马来酸罗格列酮抑制A549细胞增殖的IC50（约为80 umol/L）相符。结论 马来酸罗格列酮能够抑制A549细胞中PGC-1a的表达与活性,进而降低细胞中的线粒体质量。这有可能是罗格列酮抑制A549细胞增殖的原因之一。     

Rosiglitazone Modulates Insulin-Induced Plasma Membrane Area Changes in Single 3T3-L1 Adipocytes

The antioxidant activity of mitochondria-targeted small molecules, SkQ1 and MitoQ (conjugates of a lipophilic decyltriphenylphosphonium cation with an antioxidant moiety of a plastoquinone and ubiquinone, respectively), was studied in aqueous solution and in a lipid environment, i.e., micelles, liposomes and planar bilayer lipid membranes. Reactive oxygen species (ROS) were generated by azo initiators or ferrous ions with or without tert-butyl-hydroperoxide (t-BOOH). Chemiluminescence, fluorescence, oxygen consumption and inactivation of gramicidin peptide channels were measured to detect antioxidant activity. In all of the systems studied, SkQ1 was shown to effectively scavenge ROS. The scavenging was inherent to the reduced form of the quinone (SkQ1H(2)). In the majority of the above model systems, SkQ1 exhibited higher antioxidant activity than MitoQ. It is concluded that SkQ1H(2) operates as a ROS scavenger in both aqueous and lipid environments, being effective at preventing ROS-induced damage to membrane lipids as well as membrane-embedded peptides.     

cAMP-dependent protein kinase A selects the excited state of the membrane substrate phospholamban

Phosphorylation of membrane proteins is a central regulatory and signaling mechanism across cell compartments. However, the recognition process and phosphorylation mechanism of membrane-bound substrates by kinases are virtually unknown. cAMP-dependent protein kinase A (PKA) is a ubiquitous enzyme that phosphorylates several soluble and membrane-bound substrates. In cardiomyocytes, PKA targets phospholamban (PLN), a membrane protein that inhibits the sarcoplasmic reticulum Ca²⁺-ATPase (SERCA). In the unphosphorylated state, PLN binds SERCA, reducing the calcium uptake and generating muscle contraction. PKA phosphorylation of PLN at S16 in the cytoplasmic helix relieves SERCA inhibition, initiating muscle relaxation. Using steady-state kinetic assays, NMR spectroscopy, and molecular modeling, we show that PKA recognizes and phosphorylates the excited, membrane-detached R-state of PLN. By promoting PLN from a ground state to an excited state, we obtained a linear relationship between rate of phosphorylation and population of the excited state of PLN. The conformational equilibrium of PLN is crucial to regulate the extent of PLN phosphorylation and SERCA inhibition.     

罗格列酮和血清脂对绵羊前体脂肪细胞分化的影响

目的探讨罗格列酮(rosiglitazone,Ros)和血清脂(serum lipid,Lip)对绵羊前体脂肪细胞分化的影响及不同组织来源的前体脂肪细胞分化影响的差异。方法用不同浓度的Ros和(或)Lip培养绵羊皮下前体脂肪细胞和肾周前体脂肪细胞,通过测量3-磷酸甘油脱氢酶(GPDH)活性和油红O染色萃取液A值分析前体脂肪细胞的分化程度和脂肪细胞充脂量的变化,应用实时荧光定量PCR检测PPARγ和LPL mRNA的表达水平。结果 Ros和Lip提高细胞GPDH活性和脂滴的沉积量(P<0.05),上调LPL mRNA表达(P<0.05),最佳浓度分别为100nmol/L和20μL/mL;最佳浓度条件下Ros的诱导作用强于Lip(P<0.05),Ros显著提高了PPARγmRNA表达量(P<0.05),而Lip对PPARγmRNA的表达没有明显影响(P>0.05);Ros和Lip共同诱导与Ros单独作用之间没有明显差异(P>0.05);在相同诱导分化条件下,皮下前体脂肪细胞的分化程度高于肾周前体脂肪细胞(P<0.05)。结论研究结果表明Ros和Lip可促进绵羊前体脂肪细胞的分化,在相同条件下,皮下前体脂肪细胞的分化能力强于肾周前体脂肪细胞。